Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Research on Human Insulin rDNA (Insuget) Safety and Efficacy in Patients With Type 2 Diabetes Mellitus

NCT05161741 is registered in ClinicalTrials.gov with Getz Pharma as lead sponsor.

NCT NCT05161741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05161741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Research on Human Insulin rDNA (Insuget) Safety and Efficacy in Patients With Type 2 Diabetes Mellitus
Lead sponsor
Getz Pharma
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2021
Completion date
November 30, 2022
Enrollment
238 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse drug event, effect of drug, type 2 diabetes treated with insulin